drugset / Trial / NCT04502862

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

NCT04502862

Phase 4 Completed 202 enrolled Sanofi Regeneron Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: * To evaluate the effect of dupilumab on additional participant reported sleep outcomes * To evaluate the effect of dupilumab on objective sleep assessment * To evaluate the effect of dupilumab on asthma symptoms * To evaluate the effect of dupilumab on lung function * To evaluate the safety of dupilumab

Timeline

Start
2020-08-10
Primary completion
2023-10-03
Completion
2023-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 200 mg Subcutaneous

Indications